TRIUS THERAPEUTICS, INC. EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENTEmployee Proprietary Information and Inventions Agreement • November 6th, 2009 • Trius Therapeutics Inc • California
In consideration of my employment or continued employment by TRIUS THERAPEUTICS, INC. (the “Company”), and the compensation now and hereafter paid to me, I hereby agree as follows:
TRIUS THERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • November 6th, 2009 • Trius Therapeutics Inc • California
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of March 19, 2008, by and among TRIUS THERAPEUTICS, INC., a Delaware corporation (the “Company”) and the investors listed on Exhibit A hereto (referred to hereinafter as the “Investors” and each individually as an “Investor”).
STEVENSON-WYDLER (15 USC 3710) COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT Between LAWRENCE LIVERMORE NATIONAL SECURITY, LLC and TRIUS THERAPEUTICS, INC. For NOVEL AGENTS FOR GRAM-NEGATIVE BIODEFENSE PATHOGENS LLNL Case No. TC02128.0 Lawrence...Cooperative Research and Development Agreement • November 6th, 2009 • Trius Therapeutics Inc
This CRADA is between LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (hereinafter referred to as “LLNS”), a limited liability company incorporated in the State of Delaware and having its statewide administration address at 2300 First Street, Suite 204, Livermore, California 94550-3153, and TRIUS THERAPEUTICS, INC. (hereinafter referred to as the “Participant”), a corporation having its principal place of business at 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121. Both LLNS and the Participant to this CRADA are hereinafter jointly referred to as the “Parties”.
EMPLOYMENT AGREEMENTEmployment Agreement • November 6th, 2009 • Trius Therapeutics Inc • California
This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of February 1, 2007 (the “Effective Date”), by and between TRIUS THERAPEUTICS, INC. (the “Company”), and JEFFREY STEIN (the “Executive”). The Company and the Executive may be hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.
WARRANT AGREEMENT To Purchase Shares of the Series A Preferred Stock of Rx3 Pharmaceuticals, Inc. Dated as of November 1, 2004 (the “Effective Date”)Warrant Agreement • November 6th, 2009 • Trius Therapeutics Inc • California
WHEREAS, Rx3 Pharmaceuticals, Inc., a California corporation (the “Company”) has or is about to enter into Master Lease Line Commitment Agreement No. BL7 and related Supplements, Master Equipment Lease Agreement No. B7 and related Equipment Schedules (collectively, the “Lease(s)”) with Forsythe Biotechnology Group, Inc., an Illinois corporation (the “Warrantholder”); and
LICENSE AGREEMENTLicense Agreement • November 6th, 2009 • Trius Therapeutics Inc • Delaware
THIS LICENSE AGREEMENT (the “Agreement”) is entered into as of January 31, 2007 (the “Effective Date”) by and between RX3 PHARMACEUTICALS, INC., a California corporation, having an address of 6310 Nancy Ridge Drive, Suite 105, San Diego, California 92121, USA (“Rx3”), and DONG-A PHARMACEUTICAL CO., LTD., a company organized under the laws of Korea, having an address of 252, Yongdu-dong, Dongdaemun-ku, Seoul 130-708, Korea (“Dong-A”).
ContractWarrant Agreement • November 6th, 2009 • Trius Therapeutics Inc • California
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED (the “1933 ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO YOU THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.
